Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, β-Blockers, Calcium Channel Blockers, Others (α-Blockers, Vasodilators, Proteinuria, etc.) ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023

Code : CMI4431

Pages :135

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Hypertension in CKD Market : Key Developments

On February 10, 2023, Bayer AG, a German multinational pharmaceutical and biotechnology company, announced an expanded indication from the European Commission granted for a label extension for Kerendia (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study.
In March 2022, Zydus Lifesciences Ltd., an India-based global lifesciences company, announced that it had received approval for its New Drug Application (NDA) from the Central Drugs Standard Control Organization (CDSCO) for Oxemia indicated for the treatment of Desidustat, a first-of-its-kind oral treatment in India for anemia associated with chronic kidney disease.
In May 2022, KBP Biosciences Holdings Limited a global biotechnology research & development ccompany, signed an exclusive licensing agreement with pharmaceutical company Xelphar to commercialize KBP-1001 in several European countries upon regulatory approval. This key partnership expanded KBP's international reach and marks its first move into the European market.
In July 2022, Kissei Pharmaceutical Co., a Japan based research-based pharmaceutical company, announced licensing agreement with Otsuka Pharmaceutical to develop and commercialize IRENE for the treatment of hypertension in Europe. This agreement provides potential expansion into an important international market upon approval.

Global Hypertension in CKD Market : Key Trends

Rising number of product launches and approvals: Increasing product launches and approvals by key players in the market is expected to drive the growth of the global hypertension in CKD market over the forecast period. For instance, on February 1, 2023, GSK plc, a U.K-based multinational pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the once-a-day treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months and are contraindicted for hypertension.